Bio-Connect

Anti-PD-1 [RMP1-30], Mouse IgG2b, kappa

AB04634-3.0
Absolute Antibody
ApplicationsFlow Cytometry, Neutralisation/Blocking, Other Application
Product group Antibodies
ReactivityMouse
TargetPdcd1
Sign in to order and to see your custom pricing.
Large volume orders?
Order with a bulk request

Overview

  • Supplier
    Absolute Antibody
  • Product Name
    Anti-PD-1 [RMP1-30], Mouse IgG2b, kappa
  • Delivery Days Customer
    9
  • Antibody Specificity
    This antibody is specific for mouse PD-1.
  • Application Supplier Note
    The original version of this antibody (rat IgG2b) was used to investigate PD-1 signaling pathways in the context of allergic sensitization and challenge in mice. Specifically, it was used to determine how PD-1 blockade affects airway reactivity and immune responses (Matsumoto et al., 2004; PMID: 14764726). The original antibody was used successfully for blocking the PD-1 pathway in combination with ex vivo TKD/IL-2-stimulated NK cells in preclinical models of glioblastoma and lung cancer. It was found that this combination therapy significantly enhanced the cytotoxic activity of NK cells compared to monotherapy. The treatment resulted in improved overall survival, massive infiltration of tumors by CD8+ cytotoxic lymphocytes and NK1.1 cells, and a reduction of PD-1+ immune cells in the tumor microenvironment. Additionally, the combined therapy maintained its anti-tumor effects even after discontinuation, suggesting long-term benefits and highlighting the potential of this combined immunotherapeutic approach (Shevtsov et al., 2019; PMID: 30967859). The original version of this antibody was used successfully in an in vitro blocking assay on EL4 cells. It was also used for FC analysis and was found to stain the cells with medium intensity compared to the other tested antibodies (Polesso et al., 2021; PMID: 33684223). This antibody was also used for the FC and FACS analyses on tumor-infiltrating immune cells (TIIs) (Yokota et al., 2021; PMID: 34355173) and murine B16-F10 and YUMM melanoma cells and T-cells subsets (Martins et al., 2022; PMID: 35864188). This antibody was tested for its binding affinity to Jurkat cells expressing mouse PD-1. It exhibited intermediate avidity for PD-1 and showed limited capability to reverse PD-1-mediated T-cell inhibition compared to other tested antibodies. It demonstrated partial epitope blocking against itself and another PD-1 monoclonal antibody, indicating its suitability for specific experimental conditions requiring PD-1 staining alongside functional assessments (Bu et al., 2022; PMID: 35925787).
  • Applications
    Flow Cytometry, Neutralisation/Blocking, Other Application
  • Certification
    Research Use Only
  • Clonality
    Monoclonal
  • Clone ID
    RMP1-30
  • Gene ID18566
  • Target name
    Pdcd1
  • Target description
    programmed cell death 1
  • Target synonyms
    Ly101; mPD-1; PD-; PD-1; Pdc; Pdc1; programmed cell death 1 protein; programmed cell death protein 1; protein PD-1
  • Host
    Mouse
  • Isotype
    IgG2b
  • Protein IDQ02242
  • Protein Name
    Programmed cell death protein 1
  • Reactivity
    Mouse
  • Storage Instruction
    -20°C,2°C to 8°C
  • UNSPSC
    12352203